SCHEMBL2351641

SCHEMBL2351641

CC(C)Oc1ccc(NC(=O)c2cccc3c2OCCN3c2ncccc2Cl)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.44
GRM4 Q14833 1/20 0.41
ALDH1A1 P00352 4/20 0.40
GRM1 Q13255 1/20 0.40
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
GPR6 P46095 2/20 0.39
POLB P06746 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
LMNA P02545 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GAA P10253 1/20 0.37
S1PR1 P21453 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2346333 0.89 L3MBTL1 (0.44) TRPV1ALDH1A1GRM1POLBMAPT
SCHEMBL2350532 0.88 ALDH1A1 (0.45) TRPV1ALDH1A1GRM1TSHRSMN1; SMN2
SCHEMBL2349779 0.86 TRPV1 (0.44) TRPV1GRM4ALDH1A1GRM1SMN1; SMN2
SCHEMBL12392851 0.84 GRM4 (0.45) TRPV1GRM4ALDH1A1GRM1SMN1; SMN2
SCHEMBL2341748 0.82 L3MBTL1 (0.43) TRPV1ALDH1A1GRM1TSHRPOLB
SCHEMBL2345220 0.82 L3MBTL1 (0.55) TRPV1ALDH1A1SMN1; SMN2POLBNPC1
SCHEMBL1548738 0.81 KDM4E (0.50) ALDH1A1TSHRSMN1; SMN2NPC1RAB9A
SCHEMBL2350722 0.81 MALT1 (0.45) TRPV1GRM4ALDH1A1GRM1SMN1; SMN2
SCHEMBL1549460 0.81 TRPV1 (0.43) TRPV1GRM4ALDH1A1GRM1SMN1; SMN2
SCHEMBL2349235 0.81 TRPV1 (0.43) TRPV1GRM4ALDH1A1GRM1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2314585-B1 Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC (JP) 2012-09-12 EP claimed
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY JAPAN TOBACCO INC. (JP) 2006-02-16 US claimed
US-8008292-B2 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2011-08-30 US disclosed
US-8008292-B2 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2011-08-30 US disclosed
US-8008292-B2 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity JAPAN TOBACCO INC. (JP) 2011-08-30 US disclosed
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY JAPAN TOBACCO INC. (JP) 2006-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035882-A1 CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY TRPV1, TRPV2, TRPA1 TRPV1 1/4885GRM4 643/4885ALDH1A1 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.